✦ LIBER ✦

Interaction of dicaproyl phosphatidylserine with recombinant factor VIII and its impact on immunogenicity

✍ Scribed by Vivek S. Purohit; Sathyamangalam V. Balasubramanian

Publisher: American Association of Pharmaceutical Scientists
Year: 2006
Tongue: English
Weight: 262 KB
Volume: 8
Category: Article
ISSN: 1550-7416
DOI: 10.1007/bf02854907

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phosphatidylserine containing liposomes

Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A

✍ Karthik Ramani; Razvan D. Miclea; Vivek S. Purohit; Donald E. Mager; Robert M. S 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 257 KB

Factor VIII (FVIII) is a multidomain protein that is deficient in hemophilia A, a clinically important bleeding disorder. Replacement therapy using recombinant human FVIII (rFVIII) is the main therapy. However, approximately 15-30% of patients develop inhibitory antibodies that neutralize rFVIII act

Effect of route of administration of hum

Effect of route of administration of human recombinant factor VIII on its immunogenicity in Hemophilia A mice

✍ Aaron Peng; Puneet Gaitonde; Matthew P. Kosloski; Razvan D. Miclea; Prashant Var 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB

Factor VIII is a multi-domain glycoprotein and is an essential cofactor in the blood coagulation cascade. Its deficiency or dysfunction causes Hemophilia A, a bleeding disorder. Replacement using exogenous recombinant Factor VIII (FVIII) is the first line of therapy for Hemophilia A. Immunogenicity,

Influence of aggregation on immunogenici

Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice

✍ Vivek S. Purohit; C. Russell Middaugh; Sathyamangalam V. Balasubramanian 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 221 KB

Recombinant human factor VIII (rFVIII), a multidomain glycoprotein is used in replacement therapy for treatment of hemophilia A. Unfortunately, 15%-30% of the treated patients develop inhibitory antibodies. The pathogenesis of antibody development is not completely understood. The presence of aggreg